mechlorethamine has been researched along with Neutropenia in 21 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with advanced stage (TNM IIB-IVB) mycosis fungoides were treated with a combination chemotherapy program consisting of bleomycin and methotrexate weekly, doxorubicin every 3 weeks, and topical nitrogen mustard daily (BAM-M)." | 7.67 | Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M). ( Adelstein, DJ; Davis, BR; Hines, JD; Zakem, MH, 1986) |
| "Fifty-six patients with newly diagnosed Stage II-IV Hodgkin disease, ages 18-77 years, were randomized to receive GM-CSF (5 microg/kg subcutaneously) or placebo from Day 7 to Day 4 before each chemotherapy administration (6 cycles of a hybrid of mechlorethamine, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine)." | 5.09 | Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. ( Aglietta, M; Amadori, S; Botto, B; Cantonetti, M; Castoldi, GL; Dammacco, F; Fagioli, F; Ferrara, R; Levis, A; Montemurro, F; Racanelli, V; Teofili, L; Volta, C, 2000) |
| "Ten patients with advanced stage (TNM IIB-IVB) mycosis fungoides were treated with a combination chemotherapy program consisting of bleomycin and methotrexate weekly, doxorubicin every 3 weeks, and topical nitrogen mustard daily (BAM-M)." | 3.67 | Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M). ( Adelstein, DJ; Davis, BR; Hines, JD; Zakem, MH, 1986) |
| "Of our 19 patients with Hodgkin's disease (age range, 6 to 20 years) treated with this regimen, 2 had clinical stage I disease, 10 had stage II, 6 had stage III, and 1 had stage IV." | 2.67 | Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence. ( Arndt, CA; Chen, MG; Gilchrist, GS; Khan, SP; Matsumoto, JM; O'Fallon, WM; Schomberg, PJ; Smithson, WA, 1994) |
| "Sixteen patients with Hodgkin's disease were treated with MOPP/ABVD and filgrastim support between January 1992 and March 1994." | 1.30 | G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. ( Gustavsson, A, 1997) |
| "Neutropenia was induced by a single tail vein injection of nitrogen mustard (NM) given 1 day before the oxygen exposure." | 1.27 | Hyperoxic lung injury in mice: effect of neutrophil depletion and food deprivation. ( Anderson, J; Friedman, H; Smith, LJ, 1988) |
| "All rabbits died of respiratory failure with pulmonary edema, and although chemotherapy decreased the number of neutrophils in the lungs by greater than 90%, it did not influence survival time or extravascular lung water content." | 1.27 | Oxygen-induced lung microvascular injury in neutropenic rabbits and lambs. ( Bland, RD; Hazinski, TA; Raj, JU, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (61.90) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, LI | 1 |
| Hong, F | 1 |
| Fisher, RI | 1 |
| Bartlett, NL | 1 |
| Connors, JM | 1 |
| Gascoyne, RD | 1 |
| Wagner, H | 1 |
| Stiff, PJ | 1 |
| Cheson, BD | 1 |
| Gospodarowicz, M | 1 |
| Advani, R | 1 |
| Kahl, BS | 1 |
| Friedberg, JW | 1 |
| Blum, KA | 1 |
| Habermann, TM | 1 |
| Tuscano, JM | 1 |
| Hoppe, RT | 1 |
| Horning, SJ | 1 |
| Nugent, KM | 1 |
| Onofrio, JM | 1 |
| Sahn, SA | 1 |
| Antony, VB | 1 |
| Weitberg, AB | 1 |
| Harmon, DC | 1 |
| Raj, JU | 2 |
| Bland, RD | 2 |
| Henderson, DK | 1 |
| Hockey, LJ | 1 |
| Vukalcic, LJ | 1 |
| Edwards, JE | 1 |
| Kernoff, L | 1 |
| Colman, J | 1 |
| Khan, SP | 1 |
| Gilchrist, GS | 1 |
| Arndt, CA | 1 |
| Smithson, WA | 1 |
| Chen, MG | 1 |
| Schomberg, PJ | 1 |
| Matsumoto, JM | 1 |
| O'Fallon, WM | 1 |
| Watkins, SM | 1 |
| Meisenberg, BR | 1 |
| Melaragno, AJ | 1 |
| Monroy, RL | 1 |
| Gustavsson, A | 1 |
| Lishner, M | 1 |
| Manor, Y | 1 |
| Kitay-Cohen, Y | 1 |
| Avishay, AE | 1 |
| Aglietta, M | 1 |
| Montemurro, F | 1 |
| Fagioli, F | 1 |
| Volta, C | 1 |
| Botto, B | 1 |
| Cantonetti, M | 1 |
| Racanelli, V | 1 |
| Teofili, L | 1 |
| Ferrara, R | 1 |
| Amadori, S | 1 |
| Castoldi, GL | 1 |
| Dammacco, F | 1 |
| Levis, A | 1 |
| Ziegler, EJ | 1 |
| Douglas, H | 1 |
| Willemze, R | 1 |
| Walker, RI | 1 |
| Herion, JC | 1 |
| Palmer, JG | 1 |
| Wallis, TS | 1 |
| Vaughan, AT | 1 |
| Clarke, GJ | 1 |
| Qi, GM | 1 |
| Worton, KJ | 1 |
| Candy, DC | 1 |
| Osborne, MP | 1 |
| Stephen, J | 1 |
| Zakem, MH | 1 |
| Davis, BR | 1 |
| Adelstein, DJ | 1 |
| Hines, JD | 1 |
| Druker, BJ | 1 |
| Rosenthal, DS | 1 |
| Canellos, GP | 1 |
| Smith, LJ | 1 |
| Friedman, H | 1 |
| Anderson, J | 1 |
| Laughlin, MJ | 1 |
| Wild, L | 1 |
| Nickerson, PA | 1 |
| Matalon, S | 1 |
| Hazinski, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389] | Phase 3 | 854 participants (Actual) | Interventional | 1999-06-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.88 |
| Arm B (Stanford V) | 0.88 |
"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.74 |
| Arm B (Stanford V) | 0.71 |
Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | participants (Number) |
|---|---|
| Arm A (ABVD) | 15 |
| Arm B (Stanford V) | 19 |
3 trials available for mechlorethamine and Neutropenia
| Article | Year |
|---|---|
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2013 |
Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1994 |
Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2000 |
18 other studies available for mechlorethamine and Neutropenia
| Article | Year |
|---|---|
Pulmonary clearance of Candida albicans in neutropenic mice.
Topics: Agranulocytosis; Animals; Candida albicans; Candidiasis; Kidney; Lung; Mechlorethamine; Mice; Neutro | 1984 |
Pathogenesis of pleural plaques. Relationship of early cellular response and pathology.
Topics: Animals; Asbestosis; Cell Count; Leukocyte Count; Macrophages; Mechlorethamine; Neutropenia; Neutrop | 1984 |
Autoimmune neutropenia, hemolytic anemia, and reticulocytopenia in Hodgkin's disease.
Topics: Adult; Agranulocytosis; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Neutrophil depletion does not prevent oxygen-induced lung injury in rabbits.
Topics: Agranulocytosis; Animals; Hemodynamics; Mechlorethamine; Neutropenia; Oxygen; Pulmonary Edema; Rabbi | 1983 |
Effect of immunosuppression on the development of experimental hematogenous Candida endophthalmitis.
Topics: Agranulocytosis; Animals; Candidiasis; Endophthalmitis; Immunosuppression Therapy; Leukocyte Count; | 1980 |
Neutropenia fails to prevent the acute phase stimulation of fibrinogen synthesis.
Topics: Agranulocytosis; Animals; Carbon Radioisotopes; Fibrinogen; Liver; Male; Mechlorethamine; Neutropeni | 1982 |
Predicting neutropenia after chemotherapy for lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cy | 1993 |
Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression.
Topics: Animals; Bone Marrow; Clinical Protocols; Disease Models, Animal; Granulocyte Colony-Stimulating Fac | 1993 |
G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antine | 1997 |
Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin's disease.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin | 1999 |
Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia.
Topics: Agranulocytosis; Animals; Blood Bactericidal Activity; Conjunctivitis; Disease Models, Animal; Mechl | 1979 |
Marrow culture in diffusion chambers in rabbits. II. Effect of competing demands for red cell and white cell production on cell growth.
Topics: Anemia; Animals; Bone Marrow Cells; Cells, Cultured; Endotoxins; Erythrocytes; Erythropoietin; Hemat | 1978 |
The role of leucocytes in the induction of fluid secretion by Salmonella typhimurium.
Topics: Animals; Cell Movement; Cholera Toxin; Ileum; Indomethacin; Leukocyte Count; Leukocytes; Ligation; M | 1990 |
Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemical and Drug Induced Li | 1986 |
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Chlorambucil; Female; Hodg | 1989 |
Hyperoxic lung injury in mice: effect of neutrophil depletion and food deprivation.
Topics: Animals; Bronchoalveolar Lavage Fluid; Food Deprivation; Lung; Male; Mechlorethamine; Mice; Mice, In | 1988 |
Effects of hyperoxia on alveolar permeability of neutropenic rabbits.
Topics: Agranulocytosis; Animals; Epithelium; Lung Diseases; Mechlorethamine; Neutropenia; Neutrophils; Oxyg | 1986 |
Oxygen-induced lung microvascular injury in neutropenic rabbits and lambs.
Topics: Agranulocytosis; Animals; Blood Pressure; Capillary Permeability; Cardiac Output; Hydroxyurea; Lung; | 1985 |